A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
← catalyst calendarNCT06979375 · readout in 270 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
200estimated
Sites
92
Countries
Australia, Czechia, Germany +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2027-05-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Interventions
- Drug: CDR132L
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMain Phase: Change in normalised microRNA-132-3p (miR-132)
measured From baseline to week 24
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed